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Abstract
A variety of novel endometrial ablation technologies are now in routine use. A subset of uteri that
had previously undergone these treatments will ultimately be evaluated by the pathologist.
However, the full spectrum of histologic changes that may result from these treatments has
received only sporadic attention. The NovaSure™ [Hologic Corporation, Marlborough, MA, USA]
endometrial ablation system is one of several available second-generation technologies and its
particular endometrial ablative power is based on the delivery of radiofrequency energy. The
present analysis was designed to decipher any histologic changes (if any) associated with the
NovaSure™ endometrial ablation system relative to benign smooth muscle tumors of the uterine
corpus. Over a one-year period, 3 uteri that had previously undergone the NovaSure™
endometrial ablation and which also had leiomyomatous mass lesions were evaluated. The
leiomyomatous mass lesions were extensively sampled and were evaluated for cellular shapes
(epithelioid change, cellular rounding, extraordinary cytoplasmic eosinophilia, clear cell change,
cytoplasmic vacuolation), nuclear changes (nucleomegaly, nucleolomegaly, multinucleation,
hyperchromasia, symplastic changes), necrosis (coagulative and/or infarct), mitotic activity,
apoptotic bodies or pyknotic cells, myxoid change, hyalinization. The three uteri were resected 61,
47 and 74 (mean 60.7) days post-ablation. After a detailed evaluation of multiple submucosal,
intramural and subserosal leiomyomata from these 3 uteri, no noteworthy histologic changes were
identified in the tumors. Since the presence or absence of tumor necrosis is one histologic criterion
by which malignant potential is assigned to uterine smooth muscle neoplasms, defining any extrinsic
processes that may establish, or contribute to this finding is clinically relevant. The findings
reported herein suggests that if a leiomyoma that was obtained from a patient that had recently
undergone the NovaSure™ endometrial ablation displays any degenerative changes such as
necrosis, the changes are probably not attributable to the ablation.
Introduction
Endometrial ablation entails the destruction of the
endometrial lining by one of several energy forms that is
delivered through a hysteroscope-like or similar instru-
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ment. Some of the available endometrial ablation tech-
nologies include The NovaSure™ system [Hologic (Cytyc)
Corporation, Marlborough, MA, USA, which ablates the
endometrial surface via radiofrequency energy], the Ther-
maChoice UBT (Gynecare Inc, Somerville, NJ, USA) and
Cavaterm (Wallsten Medical, Morges, Switzerland) sys-
tems (which deliver thermal energy from heated fluid in a
balloon), the HerOption system [American Medical Sys-
tems Inc, Minnetonka, MN, USA, which is based on freez-
ing the endometrium surface], the HTA system [BEI
Medical/Boston Scientific, Natick, MA, USA, which is
based on the use of heated saline], and the Microsulis sys-
tem [Microsulis Medical Ltd, Pampano Beach, FL, USA,
which is based on microwave energy].
As noted previously, NovaSure™ is one of several second-
generation endometrial ablation systems and has been
used with increasing frequency over the past decade. The
NovaSure™ system received approval from the United
States Food and Drug Administration (FDA) in 2001 for
the permanent ablation of the endometrial lining of
women with menorrhagia that can be attributed to non-
neoplastic causes [1,2]. The endometrial ablative power is
derived from radiofrequency energy. Briefly, a conforma-
ble bipolar electrode array that is mounted on an expand-
able frame is transcervically inserted into the endometrial
cavity. The array expands to form a confluent lesion on
the entire internal surface of the endometrium. Radiofre-
quency energy is then transmitted for a period of approx-
imately 90 seconds, and the endometrium and the
superficial myometrium are thereby ablated. Increasing
tissue depth of ablation causes an automatic cessation of
power-delivery at a threshold of 50 ohms or at 120 sec-
onds, and the maximum power requirements are prede-
termined [1,2] Recently, we encountered a distinctive
uterus that was removed from a patient who had under-
gone the NovaSure™ endometrial ablation and received a
gonadotropin-releasing hormone receptor agonist (Leu-
prolide acetate) within the 7 months that preceded her
hysterectomy. The leiomyomata in the sample displayed
extensive infarct-type degeneration, which we attributed
to the Leuprolide acetate pretreatment. However, the case
raised the possibility that the NovaSure™ endometrial
ablation may have contributed to the observed changes.
The present analysis was designed to decipher any histo-
logic changes (if any) associated with the NovaSure™
endometrial ablation system relative to benign smooth
muscle tumors of the uterine corpus, since degenerative
changes such as necrosis are components of the diagnostic
criteria by which pathologists assign malignant potential
to these tumors.
Case presentations
Three uteri that had previously undergone the NovaSure™
endometrial ablation and which also had leiomyomatous
mass lesions were evaluated in detail to determine if this
treatment is associated with any morphologically recog-
nizable changes. The 3 cases represented all such cases
evaluated over a one-year period. The first and second
patients, a 49-year-old African-american (case 1) and a
45-year old caucasian (case 2), both presented with long-
term menorrhagia that was refractory to a variety of treat-
ments. They underwent the NovaSure™ endometrial abla-
tion without complications. Sixty-one (case 1) and 47
(case 2) days later, they each underwent a simple hyster-
ectomy for persistent menorrhagia. The third patient, a
51-year-old caucasian (case 3), underwent the ablation
procedure for persistent menometrorrhagia, and similarly
underwent a simple hysterectomy for persistent bleeding
74 days after the ablation. None of the 3 patients received
hormonal treatments for their uterine masses. The cut sur-
faces of all the leiomyomata in all 3 cases displayed their
typical whorled appearance and none displayed any evi-
dence of degeneration or hemorrhage. In the case 1
uterus, there was a solitary, 7.8 cm intramural mass in the
posterior wall of the corpus. This mass was 0.9 cm from
the endometrial surface at the closest point. Twenty-five
large sections were processed from this mass. In the case 2
uterus, there were a total of 4 corporal masses, including
1 submucosal (1.4 cm), intramural (5.7 cm), and 2 subse-
rosal (1.1 cm, 2.4 cm). A total of 35 large sections were
processed from these masses. In the case 3 uterus, there
were 2 posterior wall masses in the corpus, one of which
was submucosal and which measured 3.7 cm in maxi-
mum dimension, and the other of which was intramural
and which measured 4.6 cm in maximum dimension. A
total of 25 large sections were processed from these
masses. All sections were then evaluated in detail for any
morphologic changes that were notably distinct from
what would typically be expected in a leiomyoma. Each
case was evaluated for cellular shapes (epithelioid change,
cellular rounding, extraordinary cytoplasmic eosi-
nophilia, clear cell change, cytoplasmic vacuolation),
nuclear changes (nucleomegaly, nucleolomegaly, multi-
nucleation, hyperchromasia, symplastic changes), necro-
sis (coagulative and/or infarct), mitotic activity, apoptotic
bodies or pyknotic cells, myxoid change, hyalinization
etc.
All cases showed typical morphologic features of benign
smooth muscle neoplasms irrespective of whether the sec-
tion was from a submucosal, intramural or subserosal
mass (figure 1). Notably, none of the leiomyomata dis-
played any necrosis or indeed any evidence of previous or
ongoing degeneration. The average mitotic index for the 3
cases was 0.4 per 50 high power fields.
Discussion
Prospective studies with long-term follow-up have shown
that the NovaSure™ endometrial ablation system is an effi-Diagnostic Pathology 2008, 3:28 http://www.diagnosticpathology.org/content/3/1/28
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cacious modality to manage menorrhagia, with very low
complication rates and high success rates regarding stop-
page of excessive bleeding [3-5]. Nevertheless, in 2.9 to
8% of cases, surgical re-intervention is necessary due to
treatment failures (persistent bleeding), complications, or
other unrelated indications that may arise after the abla-
tion [3-6]. The resultant uteri thereby come to pathologic
attention and may show distinctive morphologic changes
[7]. We previously reported the pathologic findings of one
uteri that was removed 38 days after the ablation. These
included a distinctive 3- to 6-mm-thick, hyalinized, sub-
endometrial band, severe endometrial stromal fibrosis,
some endometrial myxoid change, and a lack of signifi-
cant changes in adenomyotic aggregates and leiomyomata
in the myometrium beneath the band [7]. Livengood et al
reported the histologic changes associated with "treat-
ment failures" of a variety of endometrial ablation tech-
nologies, NovaSure™ included [8] The authors found that
for water-balloon and radiofrequency based modalities,
persistent post-ablation bleeding is related to "treatment-
related thermally-fixed vessels" [8]. There are no other
published studies specifically centered on the histologic
changes associated with ablation technologies to the
author's knowledge. The importance of defining the histo-
logic spectrum brought about by these modalities lies not
only in the better understanding of changes associated
with failures of these treatments, but in not misclassifying
an iatrogenic change as a biologic and/or neoplastic one.
In the present analysis, the authors segregated three leio-
myomata-laden uteri that had previously undergone the
NovaSure™ endometrial ablation over a one-year period,
to determine if this treatment is associated with any mor-
phologically recognizable changes in the smooth muscle
tumors. After a detailed evaluation of such neoplasms, no
distinctive histologic changes were identified.
It is concluded that the NovaSure™ endometrial ablation
probably does not cause any morphologically recogniza-
ble changes to leiomyomata being evaluated at an average
of 60.7 days after treatment. It is unclear if tumors
removed within a shorter time-frame post-ablation will
display any changes. However, hysterectomies are typi-
cally performed within the time frames noted herein,
when sufficient time has passed post-ablation for all par-
ties to be convinced of its ineffectiveness for that particu-
lar patient, and for a surgical procedure to be scheduled.
Since the presence or absence of tumor necrosis is one his-
tologic criteria by which malignant potential is assigned
to uterine smooth muscle neoplasms, defining any extrin-
sic processes that may establish, or contribute to this find-
ing is clinically relevant. The findings reported herein
suggests that if a leiomyoma that was obtained from a
patient that had recently undergone the NovaSure™
endometrial ablation displays any degenerative changes
such as necrosis, the changes are probably not attributable
to the ablation.
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A submucosal leiomyoma from case 2 displaying typical cyto- logic features Figure 1
A submucosal leiomyoma from case 2 displaying typ-
ical cytologic features.(hematoxylin and eosin, 180×).